A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2016 Status changed from not yet recruiting to recruiting.
- 19 Nov 2015 New trial record